Rituximab in Rheumatoid Arthritis Lung Disease

Completed · Phase 3

Conditions studied: Rheumatoid Arthritis, Interstitial Pneumonia

In brief

This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physical exams and laboratory parameters. * Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological subtype) will be enrolled * The study involves 12 visits over 48 weeks * Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at six months.

Key facts

Study ID: NCT00578565
Run by: Eric Matteson
People needed: 10
Starts: 2007-05-01
Expected to finish: 2011-06-01
Last updated by the study team: 2012-10-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of RA according to the revised 1987 American Rheumatism Association criteria
Absence of clinical features suggesting infection, neoplasm, sarcoidosis, interstitial lung disease other than UIP or NSIP, other collagen vascular disease, or exposure to known fibrogenic drugs or environmental factors
Diagnosis of progressive interstitial pneumonia of UIP or NSIP subtype, based on the following criteria
Clinical symptoms consistent with interstitial lung disease with onset between 3 months and 36 months prior to screening.
Worsening as demonstrated by any one of the following within the past year:
> 10% decrease in Forced Vital Capacity (FVC)
increasing infiltrates on chest X-ray or High Resolution Computed Tomography (HRCT), or worsening dyspnea at rest or on exertion
Diagnosis of UIP or NSIP by either of the following:
Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or probable UIP or NSIP
HRCT scan showing definite or probable UIP or NSIP AND abnormal pulmonary function tests (reduced FVC or decreased diffusing capacity of carbon monoxide (DLco) or impaired gas exchange at rest or with exercise) AND insidious onset of otherwise unexplained dyspnea or exertion and bibasilar, inspiratory crackles on auscultation
FVC > 50% of predicted value at Screening
DLco >30% of predicted value at Screening
No change of disease-modifying anti-rheumatic drug (DMARD) treatment within the last 3 months

You may not qualify if…

History of clinically significant environmental or drug exposure known to cause pulmonary fibrosis.
Forced expiratory volume in one second (FEV1) FEV1/FVC ratio < 0.6 at screening (pre- or post-bronchodilator).
Residual volume > 120% predicted at Screening
Evidence of active infection
Any pulmonary condition other than UIP/NSIP, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year
History of unstable or deteriorating cardiac or neurologic disease
Pregnancy or lactation
Treatment with cyclophosphamide, cyclosporine, interferon gamma or beta, anti-tumor necrosis factor therapy, anti-interleukin 1 (IL1) therapy or with endothelin receptor blockers within the last 8 weeks; experimental therapy for rheumatoid arthritis
Creatinine > 1.5 X upper limit of normal range (ULN) at Screening
Hematology outside of specified limits: white blood cell (WBC) < 2,500/mm\^3 or absolute neutrophil count (ANC) < 1500
Hematocrit < 27% or > 59%, platelets < 100,000/mm\^3 at screening
Positive hepatitis B or C serology
Any medical condition, which in the opinion of the site principal investigator, may be adversely affected by the participation in this study
History of recurrent significant infection or history of recurrent bacterial infections
Known active bacterial, viral fungal mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
Abnormal neurological examination reflective of central nervous disease, including paresis, cognitive impairment and problems with coordination
Current enrollment in another clinical trial
Fever (>99.5º F)
History of previous rituximab administration
Receipt of any vaccine, particularly live viral vaccines, within 4 weeks of first study dose
Decreased Immunoglobulin G (IgG) and Immunoglobulin M (IgM) levels (below lower limit of normal range)
Present or past malignancy
History of severe allergic or anaphylactic reaction to administration of humanized or murine monoclonal antibodies
Positive human immunodeficiency virus (HIV) serology

Where it is running

Brigham and Women's Hospital — Boston, Massachusetts, United States
Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.